SCHEMBL6046155

SCHEMBL6046155

O=C(Nc1c(Br)c(C(=O)NCCC2CCN(c3ccncc3)CC2)nn1-c1cccc(C(F)(F)F)c1)c1ccccc1Cl

nearest known ligand 0.82

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 15/20 0.82
CHRM4 P08173 2/20 0.43
CHRM2 P08172 1/20 0.41
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1722930 0.91 BDKRB1 (1.00) BDKRB1CHRM4CHRM2
SCHEMBL4701059 0.89 BDKRB1 (0.66) BDKRB1CHRM4CHRM2KMT2A
SCHEMBL6045936 0.88 BDKRB1 (0.88) BDKRB1CHRM4
SCHEMBL6046044 0.85 BDKRB1 (0.86) BDKRB1CHRM4KMT2A
SCHEMBL6045991 0.85 BDKRB1 (0.59) BDKRB1CHRM4
SCHEMBL6046189 0.85 BDKRB1 (1.00) BDKRB1KMT2A
SCHEMBL6046018 0.84 BDKRB1 (1.00) BDKRB1CHRM4
SCHEMBL6047131 0.84 BDKRB1 (1.00) BDKRB1CHRM4
SCHEMBL14085030 0.83 BDKRB1 (0.83) BDKRB1CHRM4CHRM2
SCHEMBL6045867 0.82 BDKRB1 (0.83) BDKRB1CHRM4CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060281733-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. 2006-12-14 US claimed
US-7417152-B2 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2008-08-26 US disclosed
US-7417152-B2 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2008-08-26 US disclosed
US-20060281733-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281733-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases BDKRB1, BDKRB2, CNR1 BDKRB1 1/4885CHRM4 1131/4885CHRM2 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.